{"id":987,"date":"2026-06-18T03:47:39","date_gmt":"2026-06-18T03:47:39","guid":{"rendered":"https:\/\/menteymanzana.com\/?p=987"},"modified":"2026-06-18T03:54:02","modified_gmt":"2026-06-18T03:54:02","slug":"ivermectina-cancer-promesa-y-realidad-clinica","status":"publish","type":"post","link":"https:\/\/menteymanzana.com\/en\/ivermectina-cancer-promesa-y-realidad-clinica\/","title":{"rendered":"The Ivermectin Case: Oncological Promise and Clinical Reality"},"content":{"rendered":"<style>\n\/* === Ocultar elementos del tema para layout custom === *\/\nbody.postid-987>.wp-site-blocks>main.wp-block-group{display:none!important}\nbody.postid-987 .wp-site-blocks>.wp-block-group.has-global-padding{padding-top:0!important}\nbody.postid-987 .wp-site-blocks>.wp-block-group>.wp-block-group:first-child{padding-top:0!important;margin-top:0!important}\nbody.postid-987 .entry-title{display:none!important}\nbody.postid-987 .wp-block-post-title{display:none!important}\nbody.postid-987 main{padding-top:0!important}\nbody.postid-987 .post-thumbnail,body.postid-987 .wp-block-post-featured-image{display:none!important;margin-top:0!important;margin-bottom:0!important}\nbody.postid-987 article>*:first-child,body.postid-987 .entry-content{margin-top:0!important;padding-top:0!important}\n\n\/* === T\u00edtulo custom === *\/\nbody.postid-987 h1.mm-custom-title{color:#fff!important;font-size:2.4em;line-height:1.2;margin:0.6em 0 0.4em;text-align:center;font-weight:800;letter-spacing:-.01em}\nbody.postid-987 h1.mm-custom-title .accent{color:#c6f432}\nbody.postid-987 .mm-subtitle{color:#c6f432;text-align:center;font-size:1.05em;font-weight:600;letter-spacing:.04em;text-transform:uppercase;margin:0 0 1.8em}\n\n\/* === Hero === *\/\nbody.postid-987 .mm-hero{margin:0 0 1.5em!important}\nbody.postid-987 .mm-hero img{width:100%;max-height:480px;object-fit:cover;display:block;border-radius:6px}\n\n\/* === Contenido === *\/\nbody.postid-987 .mm-content h2{color:#c6f432!important;font-size:1.55em;margin:1.8em 0 .7em;clear:both;border-bottom:2px solid rgba(198,244,50,.25);padding-bottom:.35em}\nbody.postid-987 .mm-content h3{color:#fff!important;font-size:1.2em;margin:1.2em 0 .55em;clear:both;width:100%}\nbody.postid-987 .mm-content p{color:#e8e8e8;line-height:1.7;margin:0 0 1em;font-size:1rem}\nbody.postid-987 .mm-content strong{color:#fff}\nbody.postid-987 .mm-content em{color:#cccccc}\nbody.postid-987 .mm-content ul{color:#e8e8e8;margin:.8rem 0 1.2rem 1.25rem;line-height:1.7}\nbody.postid-987 .mm-content ul li{margin-bottom:.4rem}\n\n\/* === Im\u00e1genes de secci\u00f3n === *\/\nbody.postid-987 .mm-content figure.mm-section-img{margin:1.4em 0 1.6em;border-radius:6px;overflow:hidden;border:1px solid rgba(198,244,50,.18);box-shadow:0 6px 18px rgba(0,0,0,.35)}\nbody.postid-987 .mm-content figure.mm-section-img img{width:100%;height:auto;display:block}\nbody.postid-987 .mm-content figure.mm-section-img figcaption{background:#1a1a1a;color:#c6f432;padding:.6rem .9rem;font-size:.85rem;font-style:italic;text-align:center;border-top:1px solid rgba(198,244,50,.2)}\n\n\/* === Callout (puntos clave) === *\/\nbody.postid-987 .mm-callout{background:rgba(198,244,50,.06);border-left:3px solid #c6f432;border-radius:4px;padding:1em 1.25em;margin:1.5em 0;color:#e8e8e8}\nbody.postid-987 .mm-callout strong{color:#c6f432}\n\n\/* === Disclaimer (notas editoriales sensibles) === *\/\nbody.postid-987 .mm-disclaimer{background:rgba(244,211,94,.06);border:1px solid rgba(244,211,94,.3);border-radius:6px;padding:1em 1.25em;margin:1.2em 0 1.6em;color:#f4d35e;font-size:.93em}\nbody.postid-987 .mm-disclaimer strong{color:#ffe680}\n\n\/* === Blockquote === *\/\nbody.postid-987 .mm-content blockquote{background:#1a1a1a;color:#fff;padding:1.1rem 1.5rem;border-radius:6px;margin:1.4rem 0;font-size:1.05rem;border-left:4px solid #c6f432}\nbody.postid-987 .mm-content blockquote .mm-source{display:block;margin-top:.6rem;font-size:.83rem;color:#c6f432;font-weight:600}\n\n\/* === Tablas === *\/\nbody.postid-987 .mm-content table{width:100%;border-collapse:collapse;margin:1.2rem 0;font-size:.88rem;background:#161616;border-radius:6px;overflow:hidden;box-shadow:0 4px 12px rgba(0,0,0,.3)}\nbody.postid-987 .mm-content table th{background:#c6f432;color:#0a0a0a;padding:.65rem .8rem;text-align:left;font-weight:800;font-size:.82rem;text-transform:uppercase;letter-spacing:.03em}\nbody.postid-987 .mm-content table td{padding:.6rem .8rem;border-bottom:1px solid rgba(255,255,255,.08);vertical-align:top;color:#d8d8d8}\nbody.postid-987 .mm-content table tr:nth-child(even) td{background:rgba(255,255,255,.025)}\nbody.postid-987 .mm-content table strong{color:#c6f432}\n\n\/* === Keyfig (datos destacados inline) === *\/\nbody.postid-987 .mm-keyfig{display:inline-block;background:#c6f432;color:#0a0a0a;font-weight:800;padding:.1rem .5rem;border-radius:3px;font-size:.92em;white-space:nowrap}\n\n\/* === Referencias === *\/\nbody.postid-987 .mm-refs{margin-top:2em;padding:1.3em 1.6em;background:rgba(198,244,50,.05);border-left:3px solid #c6f432;border-radius:4px}\nbody.postid-987 .mm-refs h3{color:#c6f432!important;margin-top:0;font-size:1.1rem}\nbody.postid-987 .mm-refs ol{padding-left:1.3rem;margin:.5em 0 0;color:#cfcfcf}\nbody.postid-987 .mm-refs li{margin-bottom:.5em;font-size:.9em;line-height:1.55}\nbody.postid-987 .mm-refs em{color:#cccccc}\n\n\/* === Mobile === *\/\n@media(max-width:680px){\n  body.postid-987 h1.mm-custom-title{font-size:1.55em}\n  body.postid-987 .mm-subtitle{font-size:.9em}\n  body.postid-987 .mm-content h2{font-size:1.3em}\n  body.postid-987 .mm-content h3{font-size:1.1em}\n  body.postid-987 .mm-content p{font-size:.95rem}\n  body.postid-987 .mm-content table{font-size:.78rem}\n  body.postid-987 .mm-content table th,body.postid-987 .mm-content table td{padding:.45rem .55rem}\n}\n<\/style>\n\n<div class=\"mm-hero\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/06\/ivermectina-01-hero.png\" alt=\"Comprimido de ivermectina sobre una balanza de laboratorio, simbolizando el contraste entre promesa y evidencia\" \/><\/div>\n\n<h1 class=\"mm-custom-title\">THE CASE <span class=\"accent\">IVERMECTIN<\/span>ONCOLOGICAL PROMISE AND <span class=\"accent\">CLINICAL REALITY<\/span><\/h1>\n<p class=\"mm-subtitle\">From preclinical enthusiasm to pharmacovigilance: what the evidence really says<\/p>\n\n<div class=\"mm-content\">\n\n<div class=\"mm-disclaimer\"><strong>Editorial note.<\/strong> This dossier is a review of preclinical literature, clinical pharmacology, and early oncological evidence. <strong>This does not constitute medical advice or a recommendation to use ivermectin to treat cancer.<\/strong> To date, there are no phase III trials demonstrating antineoplastic efficacy in humans, and agencies such as the <strong>FDA<\/strong> and organisms such as <strong>NCI<\/strong> y <strong>DISGUST<\/strong> Its use outside of clinical trials is discouraged. Self-medication with ivermectin carries documented risks of toxicity. The aim is to rigorously document what the available evidence says\u2014and what it doesn&#039;t say.<\/div>\n\n<p>Few drugs have followed such a unique arc as the <em>ivermectin<\/em>. Born from Japanese soil in the late sixties, it rose to prominence with a <strong>Nobel Prize in 2015<\/strong> For eradicating parasitic diseases in millions of people, it became a symbol of controversy during the COVID-19 pandemic and is now being touted as a potential cancer treatment. This latest phase is the focus of this dossier.<\/p>\n\n<p>The scientific narrative contains a central tension. In the laboratory, ivermectin exhibits reproducible, multi-target antitumor properties that have excited researchers worldwide. In the human body, however, it encounters a seemingly insurmountable pharmacokinetic barrier and a near-total absence of clinical trials demonstrating any benefit. Between these two extremes, a torrent of misinformation has taken hold, pushing vulnerable patients toward self-medication.<\/p>\n\n<p>The purpose of the following pages is to trace the journey of the molecule from the laboratory bench to the (almost) bedside of the patient, carefully separating what is proven from what is extrapolated.<\/p>\n\n<div class=\"mm-callout\"><strong>The essentials in three lines.<\/strong> Ivermectin shows reproducible antitumor effects <em>in vitro<\/em> and in mice through multiple pathways (Wnt, PI3K\/Akt\/mTOR, mitochondrial Complex I). But the concentrations that achieve this effect are on the order of <span class=\"mm-keyfig\">~100\u00d7<\/span> higher than what the human body can safely achieve. Clinical evidence in humans is minimal and, so far, has not shown any benefit; authorities advise against its use outside of clinical trials.<\/div>\n\n<h2>Module 1 \u2014 From antiparasitic to oncology candidate: the pharmacokinetic wall<\/h2>\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/06\/ivermectina-02-modulo1-farmacocinetica.png\" alt=\"Comprimidos de ivermectina y vial junto a una curva de concentraci\u00f3n plasm\u00e1tica\" \/><figcaption>The pharmacokinetics of ivermectin impose a plasma ceiling that conditions its entire oncological application.<\/figcaption><\/figure>\n\n<h3>A Nobel Prize-winning and repositioned molecule<\/h3>\n<p>Ivermectin is a semi-synthetic derivative of avermectins, macrocyclic lactones discovered in <strong>1967<\/strong>. The work of <strong>Satoshi Omura<\/strong> y <strong>William C. Campbell<\/strong> it was worth it to them <strong>Nobel Prize in Medicine in 2015<\/strong>. Approved for human use by the <strong>FDA in 1987<\/strong>, It has treated onchocerciasis (river blindness), strongyloidiasis, lymphatic filariasis and scabies, with billions of doses administered and a wide safety margin at antiparasitic doses.<\/p>\n\n<p>He <em>drug repositioning<\/em> \u2014giving new uses to already approved drugs\u2014 is an attractive strategy: it saves years of development and is based on a known safety profile. Following this logic, preclinical evidence began to reveal unexpected pleiotropic properties in ivermectin: antiviral, antibacterial, anti-inflammatory, and, notably, antineoplastic.<\/p>\n\n<h3>The plasma ceiling: nanograms versus micromoles<\/h3>\n<p>Here the first crack appears. Ivermectin is a bulky molecule (<span class=\"mm-keyfig\">~875 Da<\/span>) and highly lipophilic (partition coefficient) <span class=\"mm-keyfig\">log P \u2248 5.8<\/span>), with poor aqueous solubility. At approved antiparasitic doses (<span class=\"mm-keyfig\">0.15\u20130.2 mg\/kg<\/span>) reaches a plasma peak of the order of <span class=\"mm-keyfig\">~50 nM<\/span>. Even pushing doses to the edge of clinical safety (<span class=\"mm-keyfig\">2 mg\/kg<\/span>), the documented peak culminates around <span class=\"mm-keyfig\">~248 ng\/mL<\/span>. These are nanomolar figures; laboratory antitumor effects require concentrations <em>micromolars<\/em>, several orders of magnitude higher.<\/p>\n\n<h3>The blood-brain barrier and P-glycoprotein<\/h3>\n<p>A second limit is biological. <strong>P-glycoprotein (P-gp\/MDR1)<\/strong>, An efflux pump in the endothelium of the blood-brain barrier actively expels ivermectin from the brain. This shield\u2014absent in the target parasites, which explains its safety in humans\u2014also prevents the drug from accumulating in intracranial tumors such as glioblastoma, except at doses that would be neurotoxic.<\/p>\n\n<h2>Module 2 \u2014 Molecular mechanisms: how it attacks the tumor cell (in vitro)<\/h2>\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/06\/ivermectina-03-modulo2-mecanismo.png\" alt=\"Visualizaci\u00f3n microsc\u00f3pica de una c\u00e9lula tumoral en apoptosis con mitocondrias resaltadas\" \/><figcaption>Ivermectin acts as a multi-target agent: it intercepts several oncogenic signaling cascades at once.<\/figcaption><\/figure>\n\n<p>Far from behaving as a non-specific toxin, ivermectin acts on several simultaneous networks. It is worth emphasizing that almost everything that follows comes from models <em>in vitro<\/em> and of animals.<\/p>\n\n<h3>Signaling pathways and resistance reversal<\/h3>\n<p>The molecule inhibits the pathway <strong>Wnt\/\u03b2-catenin<\/strong> (blocking the TCF effector), implicated in colorectal and gastric cancers, and suppresses the axis <strong>PI3K\/Akt\/mTOR<\/strong>, This induces apoptosis and inhibits angiogenesis. One particularly cited finding is that by binding to the extracellular domain of the receptor <strong>EGFR<\/strong> and block the ERK\/Akt\/NF-\u03baB cascade, downregulate P-gp synthesis in the tumor and <em>reverses multidrug resistance<\/em>, resensitizing tumor cells to chemotherapy drugs such as doxorubicin or paclitaxel.<\/p>\n\n<h3>Mitochondria, hypoxia, and radiosensitization<\/h3>\n<p>Ivermectin inhibits the <strong>Complex I<\/strong> of the mitochondrial respiratory chain (oxidative phosphorylation), which triggers reactive oxygen species and, by reducing the tumor&#039;s oxygen consumption, alleviates tissue hypoxia. Since radiotherapy requires oxygen to repair DNA damage, this reoxygenation could reverse radioresistance in glioma and lung models. The same metabolic shock affects the <strong>cancer stem cells<\/strong>, OXPHOS-dependent, suppressing pluripotency regulators such as OCT-4, SOX-2 and NANOG.<\/p>\n\n<h3>From the \u201ccold\u201d tumor to the \u201chot\u201d tumor\u201d<\/h3>\n<p>In triple-negative breast cancer models (murine 4T1 cell line), ivermectin alone barely reduced the tumor, but caused a robust infiltration of T lymphocytes, transforming an immunologically &quot;cold&quot; tumor into a &quot;hot&quot; one and enabling a marked synergy with anti-PD-1\/PD-L1 immunotherapy. This is the hypothesis that supports the current clinical trials.<\/p>\n\n<table>\n<thead><tr><th>Diana \/ Via<\/th><th>Observed effect<\/th><th>Oncological consequence<\/th><\/tr><\/thead>\n<tbody>\n<tr><td><strong>Wnt\/\u03b2-catenin<\/strong><\/td><td>Inhibition of the TCF effector<\/td><td>Cell cycle arrest (G1\/S)<\/td><\/tr>\n<tr><td><strong>PI3K\/Akt\/mTOR<\/strong><\/td><td>Akt and mTOR dephosphorylation<\/td><td>Apoptosis; decreased angiogenesis<\/td><\/tr>\n<tr><td><strong>Complex I (OXPHOS)<\/strong><\/td><td>Inhibition of mitochondrial respiration<\/td><td>Oxidative stress; reoxygenation; radiosensitization; stem cell death<\/td><\/tr>\n<tr><td><strong>EGFR \u2192 P-gp<\/strong><\/td><td>Receptor blockade and drop in P-gp transcription<\/td><td>Reversal of chemoresistance (MDR)<\/td><\/tr>\n<tr><td><strong>Microenvironment (TME)<\/strong><\/td><td>T lymphocyte recruitment<\/td><td>\u201cHot\u201d tumor; synergy with anti-PD-1\/PD-L1<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<h2>Module 3 \u2014 Preclinical efficacy by tumor and synergies<\/h2>\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/06\/ivermectina-04-modulo3-preclinica.png\" alt=\"Placas de cultivo celular y modelo animal en un laboratorio de investigaci\u00f3n\" \/><figcaption>The preclinical spectrum is broad, but it is obtained in cultures and rodents, not in patients.<\/figcaption><\/figure>\n\n<p>The scrutiny <em>in vitro<\/em> e <em>in vivo<\/em> It has a broad spectrum of activity. In digestive tumors (gastric, colorectal, hepatocellular carcinoma), ivermectin inhibits proliferation via the Wnt pathway. In gynecologic oncology, it blocks ovarian cells through importin. <strong>KPNB1<\/strong> and inhibits DNA repair. In hematology, it induces selective cell death in leukemia cell lines (such as K562) through chloride-dependent membrane hyperpolarization, sparing healthy bone marrow precursors. And in lung cancer (NSCLC, H1299 cell line) and metastatic melanoma (B16F10), it inhibits proliferation and dismantles neutrophil extracellular traps (NETs) associated with metastasis.<\/p>\n\n<h3>The likely future: adjuvant, not monotherapy<\/h3>\n<p>Modern oncology relies on combination therapies, and evidence suggests that the role of ivermectin, if any, would be to <strong>sensitizer<\/strong>. Preclinical synergies have been documented with paclitaxel and cisplatin (ovary), with dasatinib, cytarabine and daunorubicin (leukemias), with statins such as pitavastatin and with recombinant methioninase (<em>rMETase<\/em>) in pancreatic and colon cancer. The common denominator: simultaneously attacking different metabolic pathways to close off the tumor&#039;s escape routes.<\/p>\n\n<p><strong>The methodological warning is unavoidable:<\/strong> These results are obtained by immersing cells in sustained concentrations of the drug for days, or by injecting mice with doses much higher\u2014proportionally\u2014than those tolerated in humans. Their direct translation to clinical practice is not automatic.<\/p>\n\n<h2>Module 4 \u2014 The translational gap and clinical reality<\/h2>\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/06\/ivermectina-05-modulo4-clinica.png\" alt=\"Protocolo de ensayo cl\u00ednico y estetoscopio sobre un escritorio hospitalario\" \/><figcaption>The real bottleneck is not biology, but pharmacokinetics and the lack of trials.<\/figcaption><\/figure>\n\n<h3>The chasm between the test tube and the patient<\/h3>\n<p>The central obstacle is quantifiable. The concentration required for the antitumor effect <em>in vitro<\/em> is of the micromolar order, while the plasma peak is safe <em>in vivo<\/em> is nanomolar: a distance of approximately <span class=\"mm-keyfig\">~100\u00d7<\/span>. This is the same mismatch that undermined the enthusiasm for ivermectin against COVID-19, where the effective dose in culture (5 \u00b5M) was about 100 times the peak achievable in blood. Forcibly reaching those concentrations in a person would require doses that would saturate P-gp and overwhelm the blood-brain barrier.<\/p>\n\n<h3>The price of forcing the dose: neurotoxicity<\/h3>\n<p>Once that defense is saturated, the molecule enters the central nervous system and disrupts glutamate-dependent chloride channels and <strong>GABA<\/strong>, with a clinical picture that may include ataxia, vomiting, seizures, coma, and death. <strong>FDA<\/strong> It expressly warns that high doses can cause seizures, coma, or death. This is not theoretical: in <strong>2026<\/strong>, clinicians of <strong>Cincinnati Children&#039;s Hospital<\/strong> They described a teenager with metastatic bone cancer who, after reading posts on social media, developed ivermectin neurotoxicity and required emergency care.<\/p>\n\n<h3>What the data in humans really shows<\/h3>\n<p>Clinical evidence is scarce and, so far, disappointing. In the rural area of <strong>Loja (Ecuador)<\/strong>, A survey of 48 patients (2020, published in 2023) found that <span class=\"mm-keyfig\">18,75 %<\/span> He claimed to be using ivermectin as an alternative cancer therapy; the oncologists consulted did not recommend it and emphasized the lack of scientific basis. The most advanced clinical trial, in the <strong>Cedars-Sinai Medical Center<\/strong> (<em>NCT05318469<\/em>, (phase 1\/2), combines ivermectin with immunotherapeutics <em>balstilimab<\/em> o <em>pembrolizumab<\/em> in metastatic triple-negative breast cancer. Their preliminary data, presented at <strong>ASCO 2025<\/strong>, No significant benefit attributable to ivermectin was shown: of 8 evaluable patients, 6 progressed, and the 2 with some response were also receiving approved immunotherapy, preventing isolation of the macrolide effect. No serious related adverse events were observed among the first 9 treated; full results are expected by the end of [year]. <strong>2026<\/strong>.<\/p>\n\n<p>The rehearsal takes over. <strong>ICONIC<\/strong> (<em>NCT07487805<\/em>) of the <strong>University of Florida<\/strong>: phase 2, randomized, with <span class=\"mm-keyfig\">80 patients<\/span>, which will compare high-dose versus intermediate-dose ivermectin added to a checkpoint inhibitor in solid tumors. In parallel, the <strong>NCI<\/strong> confirmed at the beginning of <strong>2026<\/strong> a study <em>preclinical<\/em> (non-clinical) on the molecule&#039;s ability to destroy cancer cells; its director, <strong>Anthony Letai<\/strong>, He tempered expectations: \u201cAt the population level, it\u2019s not going to be a universal cure.\u201d The state of <strong>Florida<\/strong> advertisement <strong>$60 million<\/strong> to investigate the drug.<\/p>\n\n<table>\n<thead><tr><th>Initiative<\/th><th>Guy<\/th><th>State \/ Result<\/th><\/tr><\/thead>\n<tbody>\n<tr><td><strong>Cedars-Sinai<\/strong> (NCT05318469)<\/td><td>Phase 1\/2 trial, ivermectin + immunotherapy, TNBC<\/td><td>No significant benefit in preliminary data (ASCO 2025); final results in 2026<\/td><\/tr>\n<tr><td><strong>ICONIC<\/strong> (NCT07487805)<\/td><td>Phase 2 trial, 80 patients, solid tumors<\/td><td>Starting recruitment (2026)<\/td><\/tr>\n<tr><td><strong>NCI<\/strong><\/td><td>Preclinical study (laboratory)<\/td><td>Ongoing; results announced \u201cin a few months\u201d<\/td><\/tr>\n<tr><td><strong>Loja, Ecuador<\/strong><\/td><td>Observational survey (48 patients)<\/td><td>18.75 % self-reported use; no clinical validation<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<h2>Balance \/ Conclusions<\/h2>\n<p><strong>First<\/strong>, The preclinical signal is real and reproducible. Ivermectin acts on multiple legitimate tumor targets (Wnt, PI3K\/Akt\/mTOR, mitochondrial complex I, EGFR\/P-gp), and its antitumor biology in culture and mice is solidly documented. It&#039;s not laboratory hype.<\/p>\n\n<p><strong>Second<\/strong>, This signal encounters a pharmacokinetic barrier that remains unresolved. The distance of <span class=\"mm-keyfig\">~100\u00d7<\/span> among the effective concentrations <em>in vitro<\/em> and safe plasma levels <em>in vivo<\/em> This is, right now, the real bottleneck; forcing the dose to save it leads to neurotoxicity.<\/p>\n\n<p><strong>Third<\/strong>, Clinical evidence in humans is minimal and, so far, has not shown any benefit. The only trial with preliminary data found no benefit attributable to the drug; there is documented harm from self-medication; and virtually all institutions (<strong>FDA<\/strong>, <strong>NCI<\/strong>, <strong>DISGUST<\/strong>) advises against its use outside of trials. Of more than <span class=\"mm-keyfig\">20.000<\/span> Publications on ivermectin and cancer, the vast majority are preclinical.<\/p>\n\n<p><strong>Room<\/strong>, The rational path is rigorous research, not self-medication. The Cedars-Sinai, ICONIC, and NCI trials should clarify within one or two years whether the molecule has a real role\u2014likely as an adjuvant\u2014or whether it joins the long list of drugs that showed promise in the test tube but failed in practice. Until then, documentary prudence dictates separating the promise from the evidence.<\/p>\n\n<div class=\"mm-refs\"><h3>Selected references<\/h3><ol>\n<li>Tang M., Hu X., Wang Y., et al. (2021). <em>Ivermectin, a potential anticancer drug derived from an antiparasitic drug.<\/em> Pharmacological Research, 163:105207. (PMC7505114)<\/li>\n<li>Juarez M., Schcolnik-Cabrera A., Due\u00f1as-Gonzalez A. (2018). <em>The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.<\/em> American Journal of Cancer Research, 8(2):317\u2013331. (PMC5835698)<\/li>\n<li>Nappi L., et al. (2022). <em>Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy.<\/em> Cureus. (PMC11008553)<\/li>\n<li>Liang Y., et al. (2020). <em>Progress in understanding the molecular mechanisms underlying the antitumor effects of ivermectin.<\/em> (PMC6982461)<\/li>\n<li>Jiang L., et al. (2019). <em>Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway.<\/em> Journal of Experimental &amp; Clinical Cancer Research. (PMC6580523)<\/li>\n<li>Dominguez-Gomez G., et al. (2020). <em>Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas.<\/em> (PMC7542384)<\/li>\n<li>(2025). <em>Ivermectin as an alternative anticancer agent: a review of its chemical properties and therapeutic potential.<\/em> Pharmaceuticals (MDPI), 18(10):1459. (PMC12566834)<\/li>\n<li>Gonzalez P., et al. (2023). <em>Outcome of ivermectin in cancer treatment: an experience in Loja-Ecuador.<\/em> Nursing Reports, 13(1). (PMC10054244)<\/li>\n<li>(2026). <em>Real-world clinical outcomes of ivermectin and mebendazole in cancer patients.<\/em> Anticancer Research, 46(6):3243.<\/li>\n<li>Yuan Y., et al. (2025). <em>A phase I\/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.<\/em> Journal of Clinical Oncology, 43(16_suppl):e13146 (ASCO).<\/li>\n<li>ClinicalTrials.gov. <em>Ivermectin in combination with balstilimab or pembrolizumab in patients with metastatic TNBC.<\/em> NCT05318469.<\/li>\n<li>ClinicalTrials.gov \/ University of Florida. <em>Ivermectin combined with immune checkpoint inhibition in cancer (ICONIC).<\/em> NCT07487805.<\/li>\n<li>Pradhan R. (2026). <em>US Cancer Institute studying ivermectin&#039;s &#039;ability to kill cancer cells&#039;.<\/em> KFF Health News\/STAT, February 10.<\/li>\n<li>The Cancer News Team (2026). <em>What cancer doctors are saying about ivermectin and cancer treatment.<\/em> Binaytara Foundation.<\/li>\n<li>Mark N. (2021). <em>Debunking ivermectin: a complete guide<\/em> (review of the IC50\/Cmax pharmacokinetic gap). ICU One Pager.<\/li>\n<\/ol><\/div>\n\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The preclinical promise of ivermectin against cancer and why clinical evidence in humans does not yet support it.<\/p>","protected":false},"author":1,"featured_media":989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[51,45],"tags":[],"class_list":["post-987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevidad-metricas","category-noticias"],"acf":{"hallazgo_clave":"Potente actividad antitumoral in vitro, pero sin eficacia cl\u00ednica demostrada en humanos a dosis seguras.","tiempo_lectura":12,"nivel_evidencia":"observacional","fuente_original":"https:\/\/clinicaltrials.gov\/study\/NCT05318469","protocolo_aplicable":false,"referencias_texto":"","tags_cientificos":"ivermectina, c\u00e1ncer, reposicionamiento farmacol\u00f3gico, Wnt\/beta-catenina, PI3K\/Akt\/mTOR, Complejo I mitocondrial, glicoprote\u00edna P, farmacocin\u00e9tica, c\u00e1ncer de mama triple negativo, inmunoterapia, NCT05318469"},"hallazgo_clave":"Potente actividad antitumoral in vitro, pero sin eficacia cl\u00ednica demostrada en humanos a dosis seguras.","tiempo_lectura":"12","nivel_evidencia":"observacional","fuente_original":"https:\/\/clinicaltrials.gov\/study\/NCT05318469","protocolo_aplicable":false,"referencias_texto":null,"tags_cientificos":"ivermectina, c\u00e1ncer, reposicionamiento farmacol\u00f3gico, Wnt\/beta-catenina, PI3K\/Akt\/mTOR, Complejo I mitocondrial, glicoprote\u00edna P, farmacocin\u00e9tica, c\u00e1ncer de mama triple negativo, inmunoterapia, NCT05318469","_links":{"self":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/comments?post=987"}],"version-history":[{"count":3,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/987\/revisions"}],"predecessor-version":[{"id":995,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/987\/revisions\/995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media\/989"}],"wp:attachment":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media?parent=987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/categories?post=987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/tags?post=987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}